fda warning letter bpc-157 2024 FDA's Overreach on Compounded Peptides FDA Peptide Update: Category 2
Description
Injection site reactions : The most common side effects are mild and short-lived, including soreness, redness, or slight swelling at the injection site
If you cancel the application If the treatment is interrupted, you endanger the success of the treatment
Even if someone believes it is just healing, the consequences can be severe
10.3748/wjg.v23.i48.8465 32 EckersleyJ
Identity and purity are characterized for every lot using two complementary analytical methods
If the half-life is genuinely under 30 minutes, the compound is cleared too rapidly
